
Zealand Pharma, a biotech firm publicly listed in Denmark, has released its first quarterly report for 2022 on Thursday.
In the first three months of the year, Zealand Pharma’s rescue pen Zegalogue has generated sales of USD 0.6m, while the firm’s insulin pump product, V-Go, booked a revenue of USD 5.3m.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app